Substituted Heterocyclic Compounds for Mental Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antipsychotic medications are associated with significant side effects such as extrapyramidal symptoms (EPS), metabolic disorders, and cardiometabolic issues, which limit their efficacy and tolerability for treating schizophrenia and other central nervous system disorders.
Innovation Solution
Development of substituted heterocyclic compounds with specific receptor agonist and antagonist activities, including 5-HT1A receptor agonism, partial agonistic activity at dopamine D2 receptors, and antagonist activity at serotonin 5-HT2A receptors, to improve the treatment of central nervous system disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If first-generation typical antipsychotics are used to control positive symptoms, then positive symptoms are improved, but extrapyramidal side effects occur and long-term efficacy for negative symptoms and cognitive impairments is lacking
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure parameters of antipsychotic compounds. Specifically, it introduces substituted heterocyclic groups (thiazole, oxazole, isoxazole, isothiazole) at different positions of the piperazine ring, which changes the pharmacological parameters of the drug to achieve selective receptor binding with improved side effect profile
Solution Approach 2:
The patent employs composite materials principle by creating complex molecular structures that combine multiple functional groups. The compounds consist of piperazine ring coupled with substituted heterocyclic groups, forming composite molecular structures that interact with multiple receptors (D2, 5-HT2A, etc.) simultaneously, thereby achieving balanced therapeutic effects
2Reliability
If atypical antipsychotics are used to provide broader therapeutic outcomes, then negative symptoms and cognitive impairments are improved, but metabolic syndrome and cardiovascular disease risk increase
Solution Approach 1:
The patent changes pharmacological parameters by designing compounds with specific receptor binding profiles. The substituted heterocyclic compounds are engineered to have selective affinity for 5-HT2A receptors and dopaminergic receptors, which alters the metabolic parameter profile compared to conventional atypical antipsychotics, reducing metabolic syndrome risk while maintaining therapeutic efficacy
3Reliability
If medication switching is performed to find the best fit for individual patients, then treatment efficacy can be optimized, but treatment complexity and time consumption increase
Solution Approach 1:
The patent applies universality by designing multi-functional compounds that simultaneously address multiple symptoms and targets. The substituted heterocyclic compounds act on multiple receptors (5-HT2A, D2, D3, alpha-1 adrenergic) with a single molecular structure, providing broad therapeutic coverage that reduces the need for medication switching and combination therapies
Data Source
AI summary
The present invention relates to substituted heterocyclic compounds represented by the general formula (I), or their isotopic forms, stereoisomers, or pharmaceutically acceptable salts thereof. The present invention also describes the method of making such compounds, pharmaceutical compositions comprising such compounds and their use in the treatment of central nervous system disorders.